LSD Analogues for Health & Longevity - Quick Reference Sheet

LSD Analogues for Health & Longevity

Created on 09/30/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Sonnet 5.5 – Audit

LSD analogues are close chemical relatives of LSD (lysergic acid diethylamide), a psychedelic drug, sold as research chemicals with no approved medical use. Interest centres on mood, anxiety, and longevity, but human evidence is thin and borrowed from LSD; longevity claims rest on early laboratory work. Risks: intense altered states lasting hours, and rises in heart rate and blood pressure. Product identity, dose, and long-term safety remain largely unmeasured. (Full Review)

Protocol

Clinical (trial) protocol
Supervised sessions, LSD 25–200 µg
Anxiety trial tested single doses across that range; depression trial used two sessions with psychotherapy
Analogue use patterns
No clinical protocol exists
Self-administered 100 µg 1P-LSD produced LSD-like effects in two volunteers; survey users report variable doses and durations
Low-dose schedules
5, 10 or 20 µg every fourth day
LSD trials: six doses, or 10 µg every third day for six weeks
Time to effect
Anxiety symptoms
Measured at 4 weeks
Main anxiety endpoint in LSD trial; no analogue trial exists
Sleep duration
Night after dosing
Low-dose LSD lengthened next-night sleep; no analogue data
Acute effects (oral)
Within about 1–2 hours
Effects last 8–12 hours

Benefits

Contraindications
  • Personal or first-degree family history of psychotic or bipolar disorder
  • Uncontrolled hypertension (above 140/90 mmHg) or low blood pressure (systolic below 85 mmHg)
  • Long QT syndrome (QTc above 450 ms in men or 460 ms in women), known arrhythmia, or heart-valve disease
  • Seizure disorder or current lithium therapy
  • Pregnancy and breastfeeding
  • Adolescents
Key Interactions
  • Selective serotonin reuptake inhibitors, SSRIs (paroxetine, fluoxetine, sertraline): monitor
  • 5-HT2A blockers and antipsychotics (ketanserin, olanzapine, risperidone): monitor
  • CYP inhibitors and inducers (bupropion, ketoconazole, rifampicin): monitor
  • Serotonergic prescription drugs (sumatriptan, tramadol, phenelzine): caution, theoretical
  • Over-the-counter decongestants (pseudoephedrine, phenylephrine): monitor
  • Serotonergic supplements (5-hydroxytryptophan, St John's wort, S-adenosylmethionine): caution, theoretical
  • Caffeine and other stimulants (guarana, yohimbine): monitor
  • Alcohol, cannabis and other psychedelics (psilocybin, mescaline): caution

Risk & Side Effects

  • Medium: Acute psychedelic effects and challenging experiences
  • Low: Severe toxicity from unverified analogues; Persistent perceptual and psychotic symptoms; Acute blood pressure, heart-rate and temperature elevation; Seizures, mainly with lithium
  • Speculative: Heart-valve damage from repeated exposure; Unknown organ toxicity; Product misidentification, impurities and dose uncertainty

Monitoring

Marker Target Why
Resting blood pressure Below 120/80 mmHg Acute rises follow LSD-type exposure
Resting heart rate 50–70 beats per minute Heart rate exceeded 100 in up to 25% after LSD
Corrected QT interval on electrocardiogram Below 430 ms Fatal arrhythmia reported with AL-LAD
Echocardiogram (heart ultrasound) No more than trivial valve leakage; no valve thickening 5-HT2B activation can scar valves with repeated exposure
Alanine and aspartate aminotransferases (liver enzymes) Each below 25 U/L Organ toxicity of analogues is unstudied
Anxiety and depression questionnaires No established target for analogues; track change from own baseline (minimal symptoms are scores of 0–4) Detects emotional worsening or improvement
Batch identity test (laboratory mass spectrometry) One labelled compound; no unlisted lysergamides or impurities Products are often misidentified

Cadence: Baseline before any exposure; blood pressure and heart rate at baseline, hourly through the effect window and at resolution on each exposure day; questionnaires at 1 week, 4 weeks and 12 weeks; then electrocardiogram and liver enzymes every 6–12 months, with echocardiography added for repeated low-dose use

Qualitative Assessment

  • Sleep quality and duration
  • Energy and mood stability
  • Cognitive clarity
  • Unusual perceptions or intrusive visual changes after exposure